Article content It’s working with a company facing intense scrutiny from American politicians and regulators, but a Canadian pharmaceutical start-up says the COVID-19 vaccine the firms are making together might be better than anything on the market. The real problem for Providence Therapeutics, says CEO Brad Sorenson, is lack of interest from Ottawa. We apologize, but this video has failed to load. Try refreshing your browser, or Canadian firm works with controversial U.S. company to make 'better' COVID vaccine, but says Ottawa not interested Back to video The Alberta company’s messenger-RNA shot could be rolling out of the Emergent Biosolutions plant in Winnipeg before year’s end, Sorenson said last week, shortly after Emergent executives underwent a public grilling by U.S. lawmakers.